, with a follow-up of 7 years, it has been shown that the truly significant event reductions, which led to the tiny absolute benefit in composite endpoint, of lowering low-density lipoprotein cholesterol (LDL-C) with ezetimibe added to simvastatin was driven by both coronary revascularization (an endpoint notoriously subject to preference that falsely inflates benefits) (3) and non-fatal myocardial infarction. Furthermore, it was not mentioned how many myocardial infarctions were procedure-related (2). Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
